Renal Safety of Ranolazine and Low-Dose Aspirin Combination

Primary Renal Risks

• Low-dose aspirin (75 mg) rarely causes acute kidney injury through idiosyncratic tubulo-interstitial nephritis, though this risk is uncommon at low doses, according to the British Journal of Pharmacology 1, 2, 3.
• The risk of aspirin-induced kidney injury increases when aspirin is combined with other NSAIDs or analgesics, as reported by the British Journal of Pharmacology 1, 2, 3.
• Aspirin can be nephrotoxic through detrimental effects on renal prostaglandins, which are critical for maintaining renal perfusion, as noted by the British Journal of Pharmacology 1, 2, 3.

High-Risk Scenarios to Avoid

• The American College of Cardiology and other guideline societies recommend avoiding the combination of ACE inhibitors or ARBs plus diuretics (the "triple therapy" combination with aspirin) due to extremely high acute kidney injury risk 5, 6, 7.
• The American Heart Association suggests that pre-existing chronic kidney disease (GFR <60 mL/min/1.73 m²) is a high-risk scenario for the combination of ranolazine and low-dose aspirin, as reported by Nature Reviews Cardiology and Praxis Medical Insights 4, 7.

Monitoring Recommendations

• The European Society of Cardiology recommends obtaining baseline serum creatinine, GFR, and potassium levels before initiating therapy with ranolazine and low-dose aspirin, as suggested by Praxis Medical Insights 5, 7.
• The American College of Cardiology advises monitoring renal function (creatinine, GFR) and serum potassium within 1-2 weeks of starting therapy, then monthly for the first 3 months, according to Praxis Medical Insights 5, 7.

Clinical Pitfalls to Avoid

• The American Academy of Family Physicians warns that low-dose aspirin is not "safe" for the kidneys and still carries NSAID-related nephrotoxicity risk, especially when combined with diuretics or RAAS blockers, as reported by American Family Physician and British Journal of Pharmacology 8, 1, 2, 3, 5.
• The National Kidney Foundation recommends being aware that ranolazine accumulates significantly in renal impairment, even mild impairment, and that elderly patients are at particularly high risk for ranolazine-induced hyperkalemia and renal dysfunction, as noted by Nature Reviews Cardiology 4.